NeuroScientific hails 80% clinical response in Crohn’s stem cell program
NeuroScientific Biopharmaceuticals has reported an 80% clinical response rate in patients treated with its StemSmart cell therapy for Crohn's disease. All five patients showed improvement, with no serious adverse events recorded. The company is advancing its therapy through further clinical trials in Australia.
- ▪Four out of five patients treated for fistulising Crohn's disease demonstrated a clinical response.
- ▪All patients recorded improvements across established Crohn's disease scoring systems.
- ▪The treatment was reported to be safe and well tolerated, with no serious adverse events.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","dateModified":"2026-05-26T02:02:10Z","datePublished":"2026-05-26T02:02:10Z","description":"NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients showing improvement.","headline":"NeuroScientific hails 80% clinical response in Crohn’s stem cell program","keywords":"Bulls N' Bears, Sharemarket, Shares","author":[{"@type":"Person","name":"Doug…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Sydney Morning Herald.